52 results about "Murine tumor" patented technology

The invention belongs to the technical field of nanometer materials, and particularly relates to a zinc oxide-gadolinium-drug composite nanoparticle, and a preparation method and application thereof. The composite nanoparticle comprises a zinc oxide nanocrystal core, a polymer shell, gadolinium (III) ions modified by coordinate bonds and surface-loaded anti-cancer drug molecules, has high stability, luminescence property and magnetic relaxation rate and can be applied to cell and small animal fluorescence imaging, magnetic resonance imaging, mouse tumor treatment and the like. The preparation method includes coating a zinc oxide nanoparticle with a polymer through two copolymerization reactions, coordinating a large quantity of carboxyl groups carried by the polymer with the gadolinium (III) ions to magnetize the nanoparticle, and loading the drug molecules onto the surface of the nanoparticle. A nanoparticle drug loading platform has a good fluorescence-magnetic resonance imaging function, high drug loading rate and high release rate, is low in toxicity and is completely degraded in mouse bodies without residues, thereby having better biosecurity and medication specificity than anti-cancer drugs.

The invention provides bispecific antibodies, a preparing method thereof and uses of the bispecific antibodies, and provides murine tumor cell lines expressing human-derived EpCAM protein and uses of the cell lines. The bispecific antibodies can set up a bridge between a target cell and a functional molecule (cell), stimulate directional immune responses, and have a wide application prospect in immunotherapy of tumor. A tumor cell in-vivo drug efficacy experiment is performed in an animal model with a complete immune system, kills tumor by utilization of immune system cells, effectively reflects drug efficacy of the bispecific antibodies mediating the immune cells to kill tumor cells, and provides a good drug efficacy assessment method for development of bispecific antibody drugs targeting immune cells and tumor cells.

The invention relates to a macrophage tumor targeting therapy system combining a photothermal therapy effect and photo-thermally responsive biotherapeutic factor release and preparation and application thereof. The unique spatial and temporal selectivity of the macrophage tumor targeting therapy system can direct at a variety of solid malignant tumors, combines tumor photo-thermal therapy with biological therapy to achieve the local targeted comprehensive treatment of the tumors and reduce the toxic and side effects of traditional treatment caused by an off-target effect. The macrophage targeting tumor system can effectively inhibit the tumor growth of mice and prolong the survival time of the tumor-bearing mice, is an excellent tumor-targeting biological preparation and has great clinicalconversion application prospects.

The invention relates to a method for preparing Lonicera macranthoides saponin and its application in treating liver cancer, breast cancer and carvical carcinoma. Said method comprises following steps: extracting Lonicera macranthoides and bud with ethanol, decoloring with active carbon, grading in macroreticular resinous column or polyamide column, washing with ethanol, basic hydrolyzing, decoloring with active carbon for the second time, crystallizing and getting said product. The invention is characterized by high productivity and purity of effective component, which is about 98%, and is especially for large- scale production. The effective dosage of Lonicera macranthoides saponin is toxic to external cancer cell, and inhibitive to mouse liver cancer H22, mouse S180 cancer and Lewis lung cancer.

Ultrasound-induced blood stasis has been observed for more than thirty years. Most of the literature has been focused on the health risks associated with this phenomenon and methods employed to prevent stasis from occurring during ultrasound imaging. To date, experimental observations have been either in vitro or invasive. The current work demonstrates ultrasound-induced blood stasis in murine tumor and nontumor tissue, observed through noninvasive measurements of optical spectroscopy, and discusses possible diagnostic uses for this previously undesirable effect of ultrasound.

The invention relates to a genetically modified cell of coexpression mouse membranous type interleukin 15 and retinoic acid early transcript 1 epsilon (Rae-1 epsilon) and a preparation method thereof. The genetically modified cell is a BaF3 cell which can stabilize the genetically modified cell of the coexpression membranous type IL-15 and Rae-1 epsilon protein. The genetically modified cell can be prepared by a method comprising the following steps: amplifying a mouse Rae-1 epsilon gene and a mouse membrane expression type IL-15 gene by a polymerase chain reaction (PCR) technology; respectively inserting the amplified mouse Rae-1 epsilon gene and the amplified mouse membrane expression type IL-15 gene into two polyclone sites of an eukaryotic expression vector pVITRO2-mcs to acquire a recombined vector; transfecting the recombined vector into a mouse tumor cell strain BaF3; and acquiring the genetically modified cell by antibiotics screening and flow cytometry sorting. The genetically modified cell can provide IFN-gamma producing killer dendritic cells (IKDC) with triple stimulating signals as an instrument for efficiently amplifying and activating the IKDC in vitro. In addition, the genetically modified cell can also be used for antineoplastic immunotherapy research.

The invention discloses a method for building a fluorescent tumor model in nude mice based on primary cells of human cerebral glioma, and belongs to the field of animal models in the medical fields. The method comprises the following steps: S1, culturing of steady-transferring cells: carrying out cell culturing by adopting an improved DMEM/F12 complete culturing medium, and massively amplifying the primary cells capable of stably expressing luciferase; S2, preparation of cell suspensions: repeatedly cleaning the cells by using the improved DMEM/F12 complete culturing medium, collecting the cell suspensions for subsequent use to ensure that the concentration of the cell suspensions is 6*10<9> cells/mL, and using the suspensions in 40 minutes after the suspensions are prepared; and S3, building of a glioma model of the nude mice: injecting the suspensions in craniums of the nude mice in situ to obtain the mice model capable of stably expressing the luciferase. The fluorescent tumor modelin nude mice based on the human cerebral glioma prepared by adopting the method has the advantages that tumor growth and pathological characteristics of the nude mice are similar to the human cerebral glioma, and growth of the tumors can be observed in real time, so that a desired research model is provided for researching glioma based on in-situ transplanting and tracing of the human cerebral glioma and researching micro-environments of the tumors.

The invention discloses a preparation method of a near-infrared fluorescent compound which accurately targets tumor cells and is activated by beta-galactosidase, wherein the structure of the fluorescent compound is shown in a formula I. The probe compound combines a substrate alphaD-galactose (alphaD-gal) recognized by beta-galactosidase with cyanine near-infrared fluorophores to introduce an alphavbeta3-integrin receptor-targeted ligand c-RGD. The ability of the ligand c-RGD targeting tumor cells is utilized for near-infrared imaging of live mouse tumors overexpressing beta-galactosidase. Theprobe has the advantages that receptor-mediated cell uptake and molecular target activation are combined to realize real-time and non-invasive detection of beta-galactosidase in living tissues. The probe can be successfully applied to improve cancer imaging and promote effective cancer diagnosis.

The invention discloses a delivery system GO-PLL-RGDS/VEGF-siRNA for delivering VEGF-siRNA, discloses a delivery carrier and a preparation method of the delivery system, discloses its nanostructure, discloses the cell uptake of the delivery system, discloses The effect of the delivery system on silencing VEGF gene is disclosed, its efficiency of down-regulating VEGF expression is disclosed, its effect on inhibiting tumor cell proliferation is disclosed, and its effect on inhibiting tumor growth in mice bearing S180 sarcoma and tumor targeting of the delivery system are disclosed effect. Therefore, the application of this gene delivery system in anti-tumor gene therapy drugs is clarified.

The invention relates to a sciatic nerve ligation subcutaneous tumor-bearing rat model and application of the sciatic nerve ligation subcutaneous tumor-bearing rat model in screening of analgesic and anti-tumor medicine. Single-side sciatic nerve ligation is conducted on an adult Wistar rat subjected to hypodermic implantation of Walker256 tumor cell suspension, the pain degree of the rat is reflected through spontaneous pain, the mechanical pain threshold value and the hot pain threshold value, and the tumor growth situation is indicated through the body weight change, the tumor formation rate and the tumor size of the rat. After the to-be-detected medicine is applied to the animal model according to the required mode and dosage, and the effect of the to-be-detected medicine on the aspect of analgesia and tumor prevention is judged by observing changes of the indexes. The experimental animal model which has the lasting and stable pain characteristic and can visually measure the tumor growth situation of the tumor of the rat is used for exploring the mechanism of promoting tumor growth through pain and used for screening the novel analgesic and anti-tumor medicine. The new carrier is provided for research and development of the novel analgesic and anti-tumor medicine.

The invention provides a host factor hPRDX5 with an anti-tumor effect, an encoding gene and application of the host factor, and belongs to the technical field of cancer treatment. The host factor hPRDX5 is a single protein component, has the advantages of good preparation repeatability and controllable quality, does not generate immunogenicity when applied to humans and has incomparable advantagescompared with ACBPs. The host gene hPRDX5 can significantly inhibit growth of in-situ pancreatic cancer tumors, and by studying the adjustment and control effects of the hPRDX5 on CD4, CD8, NKT and MDSCs cells in a tumor immunity micro-environment of a pancreatic cancer mouse, it is discovered that compared with a control group, the proportion of CD4+T, CD8+T and NKT cells in pancreatic tumor tissue is significantly increased after treatment by the hPRDX5. Therefore through application of the host factor hPRDX5 in preparation of anti-tumor drugs, the tumor load can be effectively reduced, andthe period of survival with tumors is prolonged.

The invention provides a humanized mouse tumor model. The humanized mouse tumor model is characterized by being obtained by transplanting human thymus tissues and CD34+ hematopoietic stem cells homologous with the thymus tissues. The humanized mouse tumor model transplanted by thymus and hematopoietic stem cells is constructed for the first time. The humanized mouse tumor model is determined to have a complete immunosuppression microenvironment, is suitable for overall evaluation of solid tumor immunotherapy, and can be applied to evaluation of feasibility and effectiveness of immunotherapy curative effects. The humanized mouse tumor model makes up for singleness and model incompleteness of existing tumor immunotherapy evaluation methods, and provides reference value for clinical research.Compared with traditional models, the humanized mouse tumor model supplements key effects of a human immune system in immunotherapy.

The present invention relates the application of a human source dcf1 gene in the inhibition of U251 glioma cell line proliferation and in the induction of U251 glioma cell line apoptosis. The present invention makes judgments for dcf1-induced U251 cell line apoptosis by the methods of immune electron microscope, atomic force microscope, CCK8 proliferation detection, JC-1 staining, and nude mouce tumor heterotopic transplantation. The results show that: the dcf1 causes mitochondrial structure lesion and membrane potential reduction by locating in mitochondria, thereby causing apoptosis-related gene expression change, and eventually leading to apoptosis. The nude mouce experiments show that the dcf1 can significantly reduce glioma tumor volume and inhibit tumor growth.

The invention discloses an anti-double-stranded DNA monoclonal antibody with antitumor activity, as well as a preparation method thereof. The monoclonal antibody is specifically bound to double-stranded DNA or can express tumor cells of the double-stranded DNA, and the double-stranded DNA comes from a BALB/c mouse complete genome DNA sequence. The method comprises the following steps: double-stranded DNA derived from BALB/c mouse tumor cells is purified; a BALB/c mouse is immunized by the purified double-stranded DNA derived from the BALB/c mouse tumor cells; and mouse spleen cells secreting high-titer anti-dsDNA antibodies and mouse B cell lymphoma are fused, screened and repeatedly cloned, so as to obtain hybridoma cell lines capable of stably secreting anti-dsDNA monoclonal antibodies. The anti-dsDNA monoclonal antibody can be specifically bound to dsDNA, can be bound to the surfaces of tumor cells, can effectively inhibit tumor growth in vitro and in vivo, and has remarkable effect of treating tumor-bearing animals.

The invention belongs to the technical field of pharmaceutical preparations and particularly relates to application of a platinum-contained drug liposome and injections thereof in preparation of medicines for treating cancers. According to the application, by optimizing a lipid carrier and a ratio of the lipid carrier to medicines and screening the type of a stabilizer, the encapsulation efficiency of the liposome is increased, the content of related substances in the injections is lowered, and the inhibition rate on the activity of HGC and SGC-7901 gastric cancer cells is high; and the preparation disclosed by the invention can be used for improving symptoms such as listlessness of a rat suffering from a tumor, inhibiting the weight of the tumor in the rat, lowering the expression of Bcl-2 and VEGF in the tumor of the rat and improving the expression of Bax in the tumor of the rat.

The invention relates to a screening method and application of anti-inflammatory active ingredient ethyl gallate in gallnut. The method is characterized in that all ingredients in the gallnut are separated through a HPLC-MS purification separation system, and the active ingredients for treating cervicitis in the gallnut are screened through in-vitro and in-vivo experiments. In-vivo pharmacologicalstudies show that the ethyl gallate has an obvious treatment effect on a cervicitis rat; the ethyl gallate can relieve the situation of red and swollen vagina of the cervicitis rat, reduce cervical secretions and inhibit the increase of cervical viscera indexes; pathological tissue section results show that the ethyl gallate can reduce infiltration of inflammatory cells, and accelerate repair ofcervical mucosal epithelium; and enzyme-linked immunosorbent assay (ELISA) tests show that the ethyl gallate can inhibit the expression of a tumor necrosis factor-alpha (TNF-alpha) of the cervicitis rat, and promote the secretion of an epidermal growth factor (EGF) and an epidermal growth factor receptor (EGFR).

The invention illuminates the inhibition effect and mechanism of celastrol on glioma vasculogenic mimicry for the first time. Observation by PAS-CD31 double-staining method indicates that celastrol can inhibit the formation of nude mouse tumor tissue VM (vasculogenic mimicry) and also can lower the expression of naked mouse glioma mimicry related proteins EphA2 and VE-cadherin, and in-vitro experiments verify that celastrol can inhibit the formation of U87 and U251 glioma cell VM through a PI3K/AKT/mTOR pathway.

The invention belongs to the technical field of bioinformatics, and discloses a non-differential gene associated with tumor cell malignant phenotypes and a screening method and application thereof, the non-differential gene interacts with a plurality of differential genes of cancerous tissues, is ubiquitous in the cancerous tissues and para-carcinoma tissues, has relatively high abundance expression and no differential expression, and can be used for screening tumor cell malignant phenotypes. And the characteristic of playing a heavy role in a network path is realized. And sorting the genes to be distinguished through an SVM model for distinguishing cancerous tissues and para-carcinoma tissues, and removing differential genes from the genes at the first 5% of the sorted genes to obtain the non-differential genes. With the non-differential gene as a target, the non-differential gene can be used for preparing drugs for preventing or treating tumors related to the non-differential gene. Whether the non-differential genes are knocked down for preventing tumors or knocked down after tumors are formed for controlling tumor development, the screened non-differential genes can inhibit the sizes of mice tumors.

The invention discloses a tumor vaccine in mice and a preparation method thereof. The vaccine contains saccharomyces cerevisiae shell glucan GP, adjuvant polyinosinic-polycytidylic acid Poly(I:C) andpolypeptide M30, which are bonded in a mass ratio of 1:(20-25):(10-12) respectively. The tumor vaccine in mice and the preparation method thereof can overcome the technical defect that the combinationof an MHC class I molecule and short peptides cannot activate CD4+T cells in the prior art, can achieve the aim of activating the CD4+T cells by introducing the specific tumor adjuvant for the firsttime, so that the tumor vaccine in mice has a function of inhibiting tumor growth; and a new thought and foundation are provided to researches and development of vaccines for treating human tumors.

The invention discloses a tumor vaccine of recombinant murine EPS8 gene, and further discloses a preparation method for the vaccine. The method comprises the following steps of: the clone of the recombinant murine rmHis-Eps8 gene and the construction of the prokaryotic expression vector for the recombinant murine rmHis-Eps8 gene: obtaining the gene fragment expressing the 440th-710th amino acid residues in the first extracellular region of the Eps8 gene by using RT-PCR, inserting pET28a prokaryotic expression vector, transferring into the Escherichia coli BL21 for a high-efficient expression, obtaining the vaccine through protein purification and condensation by ultrafiltration columns. The obtained vaccine can prolong the survival time of 4T1 tumor-bearing mouse, inhibiting the proliferation of 4T1 breast carcinoma cells in the mice, providing a new strategy for treatment of recurrent malignant tumors which are hard to treat clinically.